On May 7, 2019 Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, reported participation in five upcoming industry conferences (Press release, Advaxis, MAY 7, 2019, View Source [SID1234535814]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioNJ 9th Annual BioPartnering Conference

Date and Time: Wednesday, May 8, 2019 at 2:00pm ET
Venue: The Palace at Somerset Park – Gatsby Suite, Somerset, New Jersey
Presenter: Molly Henderson, Executive Vice President and Chief Financial Officer
Presentation: Corporate overview
Frontiers in Cancer Immunotherapy

Date: Tuesday, May 14, 2019
Venue: The New York Academy of Sciences, New York, New York
Presenter: Robert Petit, Ph.D., Chief Scientific Officer
Two Poster Presentations: Safety and Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in Cancer Patients; and Effects of ADXS-PSA With or Without Pembrolizumab on Survival and Antigen Spreading in Metastatic, Castration-Resistant Prostate Cancer Patients (Results from KEYNOTE-046)
Immuno-Oncology Xchange

Date and Time: Wednesday, May 15, 2019 at 12:30pm ET
Venue: Seaport World Trade Center, Boston, Massachusetts
Presenter: Andres A. Gutierrez, M.D. Ph.D., Chief Medical Officer
Presentation: Challenges of First-in-Human Phase I Dose-Escalating Trials in Patients with Advanced Cancers
BIO International Convention

Date: June 3-6, 2019
Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania
Management holding partnering meetings: Ken Berlin, President and Chief Executive Officer, and Molly Henderson, Executive Vice President and Chief Financial Officer
IO Combinations 360°

Date and Time: June 20-21, 2019 at 12:00pm ET
Venue: Wyndham Historic District Hotel, Philadelphia, Pennsylvania
Presenter: J. Randolph Hecht M.D., Professor of Clinical Medicine, David Geffen School of Medicine at UCLA and Director of the UCLA Gastrointestinal Oncology Program
Presentation: A Phase 1 Dose-Escalation Study of ADXS-NEO Expressing Personalized Tumor Antigens in Subjects with Advanced Solid Tumors: Updated Results